Promising Mesenchymal Stem Cell Intervention for Relieving Cardiac Recovery against Cardiotoxic Injury Modeling with Doxorubicin: A Novel Therapeutic Approach

Basit Öğe Kaydı
dc.authorid0000-0001-7039-8956
dc.authorid0000-0002-8473-0072
dc.authorid0000-0002-8075-9564
dc.contributor.authorBoztok Özgermen, Deva Başak
dc.contributor.authorHaydardedeoğlu, Ali Evren
dc.contributor.authorYavuz, Orhan
dc.date.accessioned2025-07-10T10:34:16Z
dc.date.available2025-07-10T10:34:16Z
dc.date.issued2025
dc.departmentVeteriner Fakültesi
dc.description.abstractDoxorubicin (DOX), a commonly used anti-neoplastic agent, has been associated with significant cardiotoxic effects, which limit its clinical utility. Recent studies suggest that mesenchymal stem cells (MSCs) may offer therapeutic potential in mitigating DOX-induced cardiotoxicity through their regenerative properties. This study aimed to evaluate the cardioprotective effects of fetal kidney-derived mesenchymal stem cells (FKD-MSCs) in a DOX-induced cardiotoxicity rat model. Thirty male Sprague-Dawley rats were divided into three groups: control, sham, and treatment. DOX (10 mg/kg) was administered to the sham and treatment groups to induce cardiotoxicity. The treatment group received intraperitoneal FKD-MSCs (2 × 106) three times at weekly intervals post-DOX administration. Immunohistochemical analyses were conducted to assess cardiac recovery. The 5-bromo-2-deoxyuridine (BrdU) labeling technique was used to track FKD-MSC localization in the cardiac tissue. The immunohistochemical findings demonstrated a significant improvement in the treatment group compared to the sham group. The BrdU-labeled FKD-MSCs were predominantly localized in cardiac muscle tissues, indicating their successful homing and integration into damaged cardiac regions. The results of the study indicate that FKD-MSCs significantly attenuated DOX-induced cardiotoxicity in rats, suggesting their potential as a novel therapeutic approach for cardioprotection. Further studies are warranted to investigate their clinical applications in managing chemotherapy-induced cardiotoxicity.
dc.identifier.doi10.2478/acve-2025-0012
dc.identifier.endpage150
dc.identifier.issn05678315
dc.identifier.issue2
dc.identifier.scopus105009259323
dc.identifier.startpage139
dc.identifier.urihttps://dx.doi.org/10.2478/acve-2025-0012
dc.identifier.urihttps://hdl.handle.net/20.500.12451/13236
dc.identifier.volume75
dc.identifier.wosWOS:001512847900001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.institutionauthorBoztok Özgermen, Deva Başak
dc.institutionauthorHaydardedeoğlu, Ali Evren
dc.institutionauthorid0000-0001-7039-8956
dc.institutionauthorid0000-0002-8473-0072
dc.language.isoen
dc.publisherSciendo
dc.relation.ispartofActa Veterinaria
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCardiotoxic
dc.subjectDoxorubicin
dc.subjectRecovery
dc.subjectStem Cells
dc.titlePromising Mesenchymal Stem Cell Intervention for Relieving Cardiac Recovery against Cardiotoxic Injury Modeling with Doxorubicin: A Novel Therapeutic Approach
dc.title.alternativeINTERVENCIJA MEZENHIMALNIM MATIČNIM ĆELIJAMA ZA UBRZAVANJE OPORAVKA SRCA OD KARDIOTOKSIČNE POVREDE DOKSORUBICINOM: NOVI TERAPIJSKI PRISTUP
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
boztok ozgermen-deva basak-2025.pdf
Boyut:
1.59 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu